GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

How Can I Verify a Japanese Treatment Plan?

Get the clinic’s exact plan number, then check the current record against the treating institution, your diagnosis, the cells, and the proposed procedure. Request the committee opinion and matching consent documents before paying. A filed regenerative-medicine plan is not product approval or proof of benefit. Japan recorded 6,743 treatment plans as of 30 June 2026; that is a count of plans, not successful treatments. Index001590173.pdf

This guide concerns regenerative medicine in Japan, not every kind of Japanese treatment plan. It is general information, not personal medical advice. Document checks cannot establish whether a treatment is suitable for you; discuss that separately with your own specialist.

How Can I Verify a Japanese Treatment Plan?

Identify what the clinic is offering

Ask whether the offer is treatment under the Act on the Safety of Regenerative Medicine, use of an approved regenerative medical product, or participation in research. These are different checks, not three interchangeable approval labels. Research can also fall under the safety law. A plan requirement depends on the intervention and legal framework, not simply on whether the provider is a private clinic. Plan

The offer What to request and match
Treatment under the safety law Filed plan number, current version, treating institution, relevant procedure, and committee opinion. Plan
An approved regenerative medical product Exact product name, approval details, and current package insert. Check the approved indication, route, conditions, and whether the proposed use matches them. 0003
Participation in research Study identifier, protocol and consent information, review details, recruitment status, and eligibility criteria. Registration identifies a study; it does not establish benefit. En top

The registration-and-compliance overview explains the terminology, while the treatment-process outline helps organize your questions. Use the official records, not these background pages, to check a specific claim.

Do not compare plan counts with product-approval counts as though they measure the same thing. The MHLW snapshot lists 6,743 treatment plans and 85 research plans separately. A PMDA presentation dated 20 May 2026 lists 28 cumulative regenerative-product approvals, including one withdrawn and one expired, leaving 26 active at that date. Products include gene therapies and cell- or tissue-based products. These are different categories and dated snapshots, not a current count of effective stem-cell treatments. 001590173.pdf000280868.pdf

Check the identifiers independently

For treatment under the safety law, request the full plan number, institution’s Japanese name and address, responsible clinician, risk class, submission or update date, and current plan documents. Ask which sections cover your diagnosis, cell source, processing method, dose, sessions, and route. The risk class determines regulatory requirements; it is not an effectiveness ranking. Plan

Start at the MHLW regenerative-medicine portal rather than an agent’s screenshot. It links to e-Regenerative Medicine for non-research procedures and to jRCT for research. Use the identifiers to locate the relevant information where publicly available. If you cannot access the record, ask the treating institution for the current official record and a way to confirm it through the responsible authority. An inaccessible page is not proof of an invalid plan, but a brochure alone does not resolve the check. IndexPlan

Confirm the treating institution directly using contact details you obtain independently. Ask who provides treatment, who processes the cells, who receives payment, and who handles emergencies. Keep those roles separate when an agent or payment company is involved.

Match the documents to your procedure

Compare the current plan, committee opinion, treatment proposal, and consent form side by side. Check the diagnosis and eligibility criteria, cell source, whether cells are cultured, dose or dosing method, number of sessions, and route. An intravenous infusion and a joint injection should not be treated as interchangeable descriptions. Ask the institution to explain any mismatch before proceeding. Plan

For example, suppose your quote describes an intravenous infusion but the supplied plan describes a joint injection. This is a hypothetical document-checking scenario, not a patient case. Ask: “Which current filed plan covers the infusion you are offering me, and where is that route stated?” Do not assume a different plan covers the offer merely because both mention stem cells.

Keep the Japanese originals with any translations. Ask for clarification if the route, dose, or diagnosis differs between versions. Documents can have different identifiers and formats; ask how they relate to the same plan rather than expecting every page to share one number.

Record the committee’s name, opinion date, conditions, and the plan version reviewed. Changes affecting safety require committee review and advance submission; MHLW distinguishes these from minor changes, which have a notification procedure. An older favorable opinion does not by itself resolve a later change in the proposed procedure, and no opinion guarantees safety or benefit. Plan

Request the cell-processing center’s name, location, and applicable permission, notification, or overseas certification details. Not every facility has the same type of record: the June 2026 MHLW snapshot distinguishes 85 permitted and 3,586 notified domestic facilities, plus 19 certified overseas facilities. Ask how the named facility and quality checks relate to the cells intended for you; the facility’s status is not approval of your treatment’s efficacy. Index001590173.pdf

Check consent and evidence separately

Before paying a deposit, request written details of the procedure, known risks and uncertainties, alternatives including standard care or no intervention, follow-up schedule, emergency arrangements, and financial terms. Check treatment costs against the quote, including tests, repeat sessions, exclusions, and cancellation terms. Ask what happens if you have a complication after returning home.

Ask a separate question about benefit: “What human evidence supports this exact intervention for my condition?” Match the diagnosis, patient group, cell type, route, study phase, sample size, comparison group, outcomes, follow-up, and adverse events. A registry entry may link to results, but registration itself is not proof of effectiveness, and results may not yet be available. En top

The FDA warns that unapproved regenerative products can cause infections, unwanted immune reactions, and other serious harm. This is U.S. safety guidance, not a statement that U.S. approval rules determine legality in Japan. Important patient and consumer information about regenerative medicine therapies Evidence for blood-forming stem-cell transplantation in selected cancers does not establish that an unrelated clinic infusion treats other diseases. Stem cell transplant

Resolve gaps before paying or travelling

Pause if the institution cannot identify the applicable plan or product, the proposed procedure differs from the documents, or risks and follow-up remain unclear. For a product-based offer, do not insist on a provision-plan number without first establishing whether that requirement applies. Ask for written answers from the treating institution, not only the intermediary.

You can send this request:

Please confirm the legal framework for my proposed treatment and send the relevant current plan or product identifier. Please identify the treating institution, the procedure and route that cover my case, any applicable committee opinion and updates, the cell-processing facility, and the consent documents. If this is research, please include the study identifier, eligibility criteria, and available results. Please also confirm total costs, follow-up, and emergency arrangements.

Keep dated copies of the response and discuss unresolved clinical questions with your own specialist before you pay or travel. Verification means identifying the correct current record and resolving mismatches, not collecting enough certificates to guarantee a good outcome. The 6,743-plan figure is a dated administrative count, not a measure of treatment success. 001590173.pdf

Need help directing a document request? Use the contact form to ask where to send your questions. Treatment suitability needs a clinician’s assessment.

Open the contact form